Zai Lab Limited Unsponsored ADR $ZLAB Shares Sold by Price T Rowe Associates Inc. MD

Key Points

• Price T Rowe Associates Inc. MD has reduced its stake in Zai Lab Limited by 3.6%, owning approximately 2.06% of the company worth around $81.97 million after selling 85,809 shares.
• Zai Lab's earnings showed a loss of ($0.37) per share, matching analysts' estimates, but its revenue fell short with $109.98 million compared to expected $125.66 million.
• Analysts have mixed ratings for Zai Lab, with six analysts rating it as a "Buy" and one as a "Hold," and a consensus price target set at $56.35.

Price T Rowe Associates Inc. MD lessened its holdings in Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB - Free Report) by 3.6% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 2,268,216 shares of the company's stock after selling 85,809 shares during the period. Price T Rowe Associates Inc. MD owned about 2.06% of Zai Lab worth $81,974,000 as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in ZLAB. RTW Investments LP acquired a new stake in Zai Lab during the 4th quarter valued at $65,714,000. Mirae Asset Global Investments Co. Ltd. grew its holdings in Zai Lab by 46,222.0% during the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,132,201 shares of the company's stock valued at $77,058,000 after purchasing an additional 2,127,598 shares in the last quarter. RA Capital Management L.P. acquired a new stake in Zai Lab during the 4th quarter valued at $33,917,000. Principal Financial Group Inc. grew its holdings in Zai Lab by 63.6% during the 1st quarter. Principal Financial Group Inc. now owns 2,884,810 shares of the company's stock valued at $104,257,000 after purchasing an additional 1,121,856 shares in the last quarter. Finally, MPM Bioimpact LLC acquired a new stake in Zai Lab during the 4th quarter valued at $20,952,000. 41.65% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Zai Lab

In other news, CEO Ying Du sold 50,000 shares of Zai Lab stock in a transaction dated Friday, August 8th. The shares were sold at an average price of $34.74, for a total value of $1,737,000.00. Following the completion of the transaction, the chief executive officer directly owned 536,962 shares of the company's stock, valued at approximately $18,654,059.88. The trade was a 8.52% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CFO Yajing Chen sold 9,618 shares of Zai Lab stock in a transaction dated Monday, June 2nd. The shares were sold at an average price of $30.00, for a total transaction of $288,540.00. Following the completion of the transaction, the chief financial officer directly owned 17,429 shares of the company's stock, valued at $522,870. This trade represents a 35.56% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 225,328 shares of company stock valued at $7,878,224. Corporate insiders own 4.96% of the company's stock.

Zai Lab Trading Up 2.7%

ZLAB stock traded up $0.88 during mid-day trading on Friday, hitting $33.10. 378,288 shares of the company were exchanged, compared to its average volume of 538,751. The company has a market capitalization of $3.70 billion, a PE ratio of -16.23 and a beta of 1.04. Zai Lab Limited Unsponsored ADR has a twelve month low of $18.60 and a twelve month high of $44.34. The firm has a fifty day simple moving average of $35.68 and a 200 day simple moving average of $34.04.

Zai Lab (NASDAQ:ZLAB - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The company reported ($0.37) earnings per share for the quarter, hitting the consensus estimate of ($0.37). The company had revenue of $109.98 million during the quarter, compared to analyst estimates of $125.66 million. Zai Lab had a negative net margin of 49.68% and a negative return on equity of 27.32%. Zai Lab has set its FY 2025 guidance at EPS. As a group, sell-side analysts anticipate that Zai Lab Limited Unsponsored ADR will post -2.58 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on ZLAB shares. Leerink Partners set a $75.00 price target on shares of Zai Lab and gave the company an "outperform" rating in a report on Monday, June 30th. Wall Street Zen lowered shares of Zai Lab from a "buy" rating to a "hold" rating in a report on Friday, June 27th. Jefferies Financial Group assumed coverage on shares of Zai Lab in a report on Monday, August 25th. They set a "buy" rating and a $52.00 price target for the company. Finally, Citigroup reissued a "buy" rating and set a $69.00 price objective (up from $66.00) on shares of Zai Lab in a report on Monday, August 11th. Six research analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat, Zai Lab presently has an average rating of "Moderate Buy" and a consensus price target of $56.35.

Zai Lab Profile

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis.